Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025Right-sizing commercial efforts to ...

The "Febrile Neutropenia - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.The clinical trials report provides an overview of the Febrile Neutropenia ...

Managing maximum tolerated dose (MTD) chemotherapy while minimizing neutropenia relies on precise complete blood count (CBC) monitoring and AI-powered diagnostics.

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its ...

Shares of rare disease drug developer X4 Pharmaceuticals took a battering after it said it will restructure its workforce and ...

Nearly one year after winning an FDA drug approval to treat an ultra-rare disease, X4 Pharmaceuticals is making layoffs that ...

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

Suggestions regarding when it is appropriate to initiate chemotherapy-induced neutropenia prophylaxis in patients with cancer and goals of therapy. January 18th 2021EP. 5: Chemotherapy-Induced ...